An Investigator-Initiated Study of Loncastuximab Tesirine Plus Rituximab for the Treatment of R/R FL

A panelist discusses how a new phase 2 study investigating the combination of loncastuximab tesirine plus rituximab in patients with relapsed/refractory follicular lymphoma aims to build upon earlier promising results by evaluating efficacy, safety, and durability of response in a larger patient population.

EP: 1.An Overview of the Current Treatment Landscape for R/R FL

EP: 2.Exploring ADC/Antibody Combination Therapies in Development for R/R FL

Now Viewing

EP: 3.An Investigator-Initiated Study of Loncastuximab Tesirine Plus Rituximab for the Treatment of R/R FL

EP: 4.Recent Safety and Efficacy Updates from the Investigator Initiated Study of Loncastuximab tesirine + Rituximab for the Treatment of R/R FL

EP: 5.Key Considerations for the Evolving Treatment Landscape for Relapsed/Refractory Follicular Lymphoma

EP: 6.Future Perspectives on the Relapsed/Refractory Follicular Lymphoma Treatment Landscape

Video content above is prompted by the following:

• Introduce the phase 2 study of loncastuximab plus rituximab in R/R FL presented at ASH 2024.

Recent Videos